Several other equities research analysts have also commented on the stock. HC Wainwright restated a “buy” rating and set a $5.00 target price on shares of Antares Pharma in a research report on Thursday, February 24th. Zacks Investment Research raised shares of Antares Pharma from a “sell” rating to a “hold” rating in a research note on Monday, March 7th.
Shares of NASDAQ ATRS traded down $0.01 during midday trading on Tuesday, hitting $3.74. The company’s stock had a trading volume of 565,966 shares, compared to its average volume of 771,241. Antares Pharma has a 1 year low of $3.11 and a 1 year high of $4.63. The business’s fifty day simple moving average is $3.77 and its two-hundred day simple moving average is $3.59. The company has a debt-to-equity ratio of 0.10, a current ratio of 2.96 and a quick ratio of 2.76. The firm has a market capitalization of $636.20 million, a price-to-earnings ratio of 13.85 and a beta of 1.52.
A number of institutional investors and hedge funds have recently made changes to their positions in ATRS. Barclays PLC increased its position in Antares Pharma by 71.2% in the fourth quarter. Barclays PLC now owns 283,332 shares of the specialty pharmaceutical company’s stock worth $1,011,000 after buying an additional 117,863 shares during the period. BlackRock Inc. boosted its stake in Antares Pharma by 1.2% during the fourth quarter. BlackRock Inc. now owns 12,023,196 shares of the specialty pharmaceutical company’s stock valued at $42,924,000 after buying an additional 147,703 shares in the last quarter. California State Teachers Retirement System boosted its stake in Antares Pharma by 1.8% during the fourth quarter. California State Teachers Retirement System now owns 226,229 shares of the specialty pharmaceutical company’s stock valued at $808,000 after buying an additional 3,976 shares in the last quarter. Parametric Portfolio Associates LLC boosted its stake in Antares Pharma by 15.5% during the fourth quarter. Parametric Portfolio Associates LLC now owns 169,579 shares of the specialty pharmaceutical company’s stock valued at $605,000 after buying an additional 22,814 shares in the last quarter. Finally, Metropolitan Life Insurance Co NY boosted its position in shares of Antares Pharma by 7.8% in the 4th quarter. Metropolitan Life Insurance Co NY now owns 45,536 shares of the specialty pharmaceutical company’s stock valued at $163,000 after purchasing an additional 3,286 shares during the period. Hedge funds and other institutional investors own 48.63% of the company’s stock.
Antares Pharma Company Profile (Get Rating)
Antares Pharma, Inc, a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. It develops, manufactures, and commercializes novel therapeutic products using its drug delivery systems.
- Get a free copy of the StockNews.com research report on Antares Pharma (ATRS)
- Insiders Are Selling Palo Alto Networks
- Greenbrier Companies Stock has Green in its Future
- Headwinds Mount For Carmax, Don’t Count On Higher Share Prices
- 3 Bank Stocks That Are Ready to Handle Whatever the Fed Throws at Them
- Tilray Stock Has Better Days Ahead
Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.